Related references
Note: Only part of the references are listed.Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Treatment of elderly patients with chronic lymphocytic leukemia
Barbara Eichhorst et al.
LEUKEMIA & LYMPHOMA (2009)
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century
Hermann Brenner et al.
BLOOD (2008)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
New prognostic markers in chronic lymphocytic leukemia
Carol Moreno et al.
BLOOD REVIEWS (2008)
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication
Francesc Bosch et al.
CLINICAL CANCER RESEARCH (2008)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sex differences in incidence and outcome of chronic lymphocytic leukemia patients
Stefano Molica
LEUKEMIA & LYMPHOMA (2006)
Interpreting trends in cancer patient survival
P. W. Dickman et al.
JOURNAL OF INTERNAL MEDICINE (2006)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
JC Byrd et al.
BLOOD (2005)
Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation computational realisation and applications
H Brenner et al.
EUROPEAN JOURNAL OF CANCER (2004)
Regression models for relative survival
PW Dickman et al.
STATISTICS IN MEDICINE (2004)
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
M Leporrier et al.
BLOOD (2001)
Share Paper
